Celiac disease, inflammatory bowel disease (Crohn’s disease and ulcerative colitis) Digestive System Coeliac disease, inflammatory bowel disease
Conditions
Interventions
We will include 50 CD patients, 50 IBD patients, and 50 non-celiac, non-IBD control subjects (age- and sex-matched inclusion after recruiting CD and IBD patients) in the first phase of the study. Then
Sponsors
Centre for Translational Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: CD patients 1. Newly diagnosed or followed-up patients (with or without adhering to a gluten-free diet (GFD) 2. Aged =18 years 3. Diagnosis should meet the current guidelines (ESPHGAN, American College of Gastroenterology) IBD patients 1. Newly diagnosed and followed-up patients 2. Aged =18 years 3. Diagnosis should meet the current guidelines (ECCO) Non-CD, non-IBD controls 1. Aged =18 years 2. Celiac disease excluded (lack of symptoms and negative celiac-specific serology) 3. IBD excluded (lack of clinical, biochemical, endoscopic or radiologic signs of the disease)
Exclusion criteria
Exclusion criteria: 1. Estimated glomerular filtration rate calculated with CKD-EPI formula <60 ml/min/1.73 m2 (CKD Stage 3 or more severe kidney failure) 2. Liver cirrhosis (Child-Pugh class B/C) 3. Heart failure (NYHA class III/IV) 4. Malignant diseases (except for cured cases) 5. Acute diseases within 2 weeks of sampling 6. Patients unable to understand the essentials of the informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemorheologic test results including erythrocyte deformability and aggregation and viscosity of whole blood and plasma The measurement of laboratory parameters will be done on the day of recruitment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Risk of arterial and venous thrombosis (determined by clinical and laboratory measures on the day of recruitment) | — |
Countries
Hungary
Outcome results
None listed